Conflicting Evidence for Silver-Impregnated Dressings in Diabetic Foot Ulcers
At a 210-bed community hospital, you chair the wound care committee. The current protocol for Wagner grade 1–2 diabetic foot ulcers uses saline-moistened gauze at $12 per change. A vendor proposes silver-impregnated foam at $47, citing a 12-week industry-funded RCT of 180 patients: complete healing 41% with silver vs 33% with gauze (p=0.08), with 28% loss to follow-up. A 2023 meta-analysis of 9 RCTs (n=1,240) reports RR 1.18 (95% CI 1.02–1.36) favoring silver, but heterogeneity is I²=62% and most trials are rated high risk of bias. A national guideline weakly recommends silver only for clinically infected ulcers. Your unit admits about 38 diabetic foot ulcers per quarter; two patients developed cellulitis last month. The CNO wants a formulary decision in 10 days and asks whether the $47 dressing should replace gauze for all ulcers.
1. Using the EBP triad, explain how you would weigh the vendor RCT, the meta-analysis, and the guideline. What additional evidence or local data would you request before voting?
Read the worked answer
Evidence-based practice rests on three legs: best available research evidence, clinical expertise, and patient values and preferences, with local context and resources as a fourth practical consideration. I would not simply count levels. The vendor RCT is a single, small, industry-funded study with a nonsignificant result (p=0.08) and 28% attrition; its effect is fragile and vulnerable to attrition bias and selective reporting. The meta-analysis provides a more precise estimate (RR 1.18, 95% CI 1.02–1.36), but the CI barely excludes no effect, heterogeneity is moderate (I²=62%), and most included trials are high risk of bias, so certainty is low. The guideline’s weak recommendation for infected ulcers only reflects that uncertainty and indirectness for noninfected ulcers. I would request the meta-analysis’s risk-of-bias table, the RCT’s CONSORT flow and intention-to-treat analysis, the absolute healing difference and number needed to treat, dressing-change labor costs, and local wound infection and amputation data. For all Wagner 1–2 ulcers, the evidence does not support replacing gauze. For infected or high-risk ulcers, a time-limited pilot may be justified.
2. Draft the focused clinical question and a committee recommendation (adopt, pilot, or reject). Include outcome measures and a plan for reassessment.
Read the worked answer
PICO: In adults with Wagner grade 1–2 diabetic foot ulcers (P), does a silver-impregnated foam dressing (I), compared with saline-moistened gauze (C), increase complete healing at 12 weeks and reduce cellulitis or infection (O) without increasing cost per healed ulcer? Recommendation: do not adopt for all ulcers; approve a 6-month pilot restricted to ulcers with clinical signs of infection or high infection risk, with wound-care-nurse oversight. The pilot should use a standardized assessment tool, photograph and measure ulcers at baseline and weekly, and track complete healing at 12 weeks, infection/cellulitis, amputation, dressing changes per week, supply cost, and patient-reported pain and comfort. Use a pre–post design with a concurrent gauze comparison group if feasible, and run monthly run charts. Stop or modify the pilot if cellulitis does not fall, healing is not improved, or cost per healed ulcer exceeds the gauze benchmark. Report the decision and rationale transparently to the committee, and reassess after 30–40 patients, not after the vendor’s 10-day deadline.